source
- Celea Therapeutics secures $180M financing to advance IPF pipelineCelea Therapeutics, an idiopathic pulmonary fibrosis (IPF) biotech, announced it has raised $180 million from a group of new investors. The funding is intended to help the company follow the devel…
- Galderma receives FDA complete response letter for anti-wrinkle neuromodulatorGalderma has been issued a complete response letter by the U.S. Food and Drug Administration for its experimental anti-wrinkle product relabotulinumtoxinA, which was under review as a neuromodulato…